🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Exploration of Allograft Humoral Rejection in Chronic Histiocytic Intervillositis

RecruitingNAAges 18 Years - anyAllAssistance Publique - Hôpitaux de Paris
NCT05936333 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Chronic histiocytic intervillositis (CHI) is a rare condition with an incidence of 5 in 10,000 pregnancies. This rare condition is associated with placental inflammatory lesions leading to severe and recurrent obstetrical complications: intrauterine growth retardation (IUGR), fetal death in utero and miscarriage. The pathophysiological mechanisms of CHI are poorly understood, while the empirical treatments prescribed to prevent recurrence are cumbersome and of poor efficacy. Recent findings suggest that an alloimmune response may play a role. In a recent work, the investigators have demonstrated the role of maternal alloantibodies directed against fetal HLA antigens in two patients followed for recurrent IUGR associated with CHI. Their work suggests that a humoral alloimmune response directed against fetal HLA antigens mimics an allograft rejection process. The investigators propose to

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Family Inclusion Criteria: * Mother and father ≥ 18 years old * For mothers in the CHI group : * History of a normal pregnancy (full term, alive child) or IUGR/MFIU or miscarriage(s) or abortion followed by at least 1 obstetrical complication such as IUGR, MFIU, miscarriage * Diagnosis of chronic histiocytic intervillitis made by placental anatomopathological examination with CD68+ marking * For the mothers of the antiphospholipid syndrom group * History of miscarriage(s) * Having an anti-phospholipid syndrome * For mothers in the normal pregnancy group: * Third consecutive pregnancy of normal course, at term (≥ 36 weeks of amenorrhea) with eutrophic child For the mother and father: o Consent to participate in the study and for the participation in the study of at least one child and/or the use of existing samples (placenta / fetal DNA) from at least one previous pregnancy with CHI for the CHI group or at least one previous miscarriage for the APS group For the father: o Father of the last pregnancy and of the child(ren) participating in the study Exlusion criteria : * For mothers in the normal pregnancy group: o Suspected or confirmed intra-amniotic infection * For all the mothers: * History of blood transfusion * History of allogeneic organ transplantation * For the mother and the father: * Person under legal protection (guardianship, curatorship)
💊

What it tests

  • Biological collection
📍

Where

1 site
Antoine Béclère Hospital
Clamart, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy